SMR

NuScale is the only U.S. company with full NRC SMR design approvals (50 MWe Design Certification 2022; 77 MWe Standard Design Approval May 2025) in a market where regulatory clearance is a multi-year, multi-hundred-million-dollar barrier. However, being first to NRC approval has not translated into first to revenue: the company has zero binding commercial contracts as of June 2026, its only firm order (UAMPS) cancelled in 2023, and better-capitalised or hyperscaler-backed rivals (Oklo, Kairos, X-energy) are closing the regulatory gap. Oklo at $11.6B market cap now exceeds NuScale's $4.5B despite holding no full NRC design certification — signalling that the market is pricing competitor pipelines and hyperscaler relationships above pure regulatory head-start. NuScale is structurally well-positioned on paper; operationally it is a pre-commercial option on the nuclear renaissance, not a cash-flowing business.

NuScale Power designs small modular nuclear reactors and licenses that technology to utilities, governments, and industrial customers. Its core product is the VOYGR plant — a scalable configuration of factory-built 77 MWe reactor modules (uprated from the original 50 MWe design) that can be assembled on-site to deliver between 77 MWe and 924 MWe (12-module VOYGR-12). NuScale does not build reactors itself; it licenses its certified design and earns engineering and licensing fees ahead of plant construction. The company holds two U.S. NRC approvals: a 50 MWe Design Certification (2022) and a 77 MWe Standard Design Approval (May 2025) — the only full NRC SMR design approvals held by any company. It has an exclusive global commercialisation partner, ENTRA1, and a manufacturing relationship with Doosan (South Korea), which reportedly has 12 VOYGR modules in production.

NuScale's commercialisation strategy centres on three parallel tracks: (1) closing the RoPower Romania Final Investment Decision (FID) for a 6-module, 462 MWe plant — the project has been in Front-End Engineering and Design (FEED) studies since 2021 and the FID has slipped from Q2 2026 to mid-late 2026 or early 2027; (2) advancing the TVA/ENTRA1 6 GW collaborative agreement (September 2025) into binding power purchase agreements (PPAs) for up to six plants across TVA's seven-state region, targeting first power ~2030; and (3) securing a DOE loan guarantee conditional commitment to remove the financing overhang that prevents customers from signing. Management has also stated that a first operating plant by 2030 is achievable "if we get closure on a deal here soon." The company's financial plan through to first commercial revenue is explicitly dependent on ongoing ATM equity issuances and potential additional offerings — the 662M authorized share ceiling (vs. a materially expanded float post-offerings and ATM activity) reflects this.

Revenue (FY, USD):

Revenue grew from $0.6M (2020) to $37.0M (2024) driven by engineering and technology licensing fees, then declined to $31.5M in FY2025 (-14.9% YoY). Q1 2026 revenue was $0.6M (per press release, not XBRL-confirmed) — a sharp quarter decline attributed to the non-recurrence of one-time Romania technology license recognition that inflated Q1 2025. Note: FY2024 revenue of $37.0M was +62.4% above FY2023's $22.8M, not a decline — the improvement was partly driven by lumpy license recognition.

Operating income (FY, USD):

FY2024 showed a genuine improvement (operating loss narrowed from -$275.6M to -$138.7M). FY2025 reversed that sharply, with the operating loss nearly 5x the prior year (-$689.6M). The FY2025 figure includes restructuring charges and non-cash items, but the underlying cash burn trajectory is consistent: operating cash flow was -$459.6M in FY2025 vs. -$108.7M in FY2024 (4.2x acceleration).

Balance sheet:

• Cash at FY2025 year-end: $836.4M (XBRL-confirmed)
• Management stated $1.0–1.2B in total liquidity as of May 2026 (press-release-sourced; not XBRL-confirmed — reflects post-quarter ATM activity and the February 2026 equity offering)
• Net loss FY2025: -$355.8M

Runway:

Using the FY2025 annual operating cash outflow of -$459.6M against the $836M FY2025 year-end cash: roughly 1.8 years of runway from the annual-rate basis. However, the Q1 2026 press-release figure of -$314.7M in a single quarter, if sustained, implies a dramatically shorter runway of approximately 3-4 quarters from the $1.0–1.2B stated liquidity. The company has no path to self-funding; continued solvency depends on the ATM program remaining open and the stock price staying above levels that make new issuance economically feasible.

Share count and dilution:

• Shares outstanding per XBRL (as of 2022-05-03 filing): 236,754,948. Actual current float is materially larger: the February 2026 equity offering added ~75.9M shares (at $13.18/share), Q1 2026 ATM added 3.16M, and post-quarter through May 7 another 22.4M were sold via ATM.
• Shareholders approved expanding authorized Class A shares to 662M from 332M.
• Fluor's 111M-share exit (Sept 2025–Apr 2026, ~$2.43B total) is fully resolved, removing the largest structural seller — a modestly positive technical clearing.

At $13.95 and $4.54B market cap, NuScale trades at approximately 144x FY2025 revenue ($31.5M) and at a roughly $3.7B enterprise value (market cap minus $836M FY2025 year-end cash — a floor calculation that does not net liabilities). All earnings-based multiples are meaningless; operating losses are -$689.6M on $31.5M revenue.

For a pre-commercial option, the relevant comparison is: what commercialisation probability does the current price imply? Analyst targets range from $7 (Citi, May 2026) to $45 (Barclays) — a 6x spread that reflects narrative speculation rather than fundamental anchoring. BofA reinstated at Neutral / $12 (May 31, 2026), citing slow contract conversion and funding vulnerability. The mid-range Canaccord target of $25 implies roughly 79% upside from current price and requires at least one binding contract materialising.

Fair value range: $7–$22 (method: scenario-weighted). The lower bound ($7, in line with Citi) reflects no binding contract by end-2026, continued ATM dilution, and a market de-rating toward the pre-revenue cash-burn multiple; this implies roughly $3.5B market cap, or ~4x current annual liquidity. The upper bound ($22) reflects the RoPower FID signed plus a DOE loan conditional commitment in 2026, re-rating the stock toward a 10x P/S on a hypothetical $150–$200M forward licensing/engineering revenue run-rate. The Barclays $45 target requires the full TVA/ENTRA1 6 GW program materialising on schedule with no current contractual basis and is not supportable on a 12-month horizon. The current $13.95 price is toward the middle of this range, reflecting the market's ambiguous pricing of commercialisation probability in the absence of any confirmed contracts.

Institutional ownership data is not available in the fact sheet. Key ownership events from external sources (not XBRL-confirmed): Fluor Corporation sold approximately 111M shares for ~$2.43B between September 2025 and April 2026, fully exiting its position — this resolved a multi-year technical overhang. Management's active ATM program and the 662M authorized share ceiling signal that ongoing equity issuance is the operational survival plan, not a contingency. No insider buyback program has been disclosed in available data. No formal going-concern opinion or auditor material weakness is cited in available filings.

NuScale is the only U.S. company with full NRC SMR design approvals in a market where regulatory clearance is a multi-year, multi-hundred-million-dollar barrier. The demand curve for firm, 24/7, low-carbon power is structurally accelerating: IEA projects U.S. data center electricity demand to roughly double to ~35 GW by 2030, and hyperscalers have collectively announced 20+ GW of advanced nuclear financing plans. At $4.54B market cap and $836M year-end cash, the enterprise value is approximately $3.7B — pricing in significant but not absurd commercialisation probability for the only NRC-cleared SMR design.

Doosan reportedly has 12 VOYGR modules already in production, meaning if a first contract is signed, hardware lead-time is partially de-risked. The Fluor overhang is fully resolved, removing the single largest structural seller for the first time since the company went public — a catalyst pop will not be absorbed by a structural seller. If RoPower FID or the TVA/ENTRA1 PPA materialises, NuScale becomes the only company with an NRC-approved design, modules in production, and a signed commercial order — a combination no peer can match today. A single binding contract would likely re-rate the stock toward the $20–25 mid-range analyst target (45–79% upside from current price).

1. Revenue collapse (HIGH severity): FY2025 revenue $31.5M, down from $37.0M in FY2024. Q1 2026 revenue $0.6M (press-release-sourced; not XBRL-confirmed) — attributed to non-recurrence of one-time Romania license recognition. The underlying engineering/licensing revenue model is inherently lumpy and thin; true reactor revenue is a 2030+ event.

2. Cash burn explosion (HIGH severity): Operating cash flow deteriorated from -$108.7M (FY2024) to -$459.6M (FY2025) — a 4.2x acceleration in one year. Q1 2026 press-release figure of -$314.7M in a single quarter (not XBRL-confirmed) implies runway compression to approximately 3-4 quarters from stated $1.0–1.2B liquidity.

3. Dilution treadmill (HIGH severity): The February 2026 equity offering added ~75.9M shares at $13.18; the ongoing ATM program added further shares; authorized shares expanded to 662M. The company's survival plan is serial equity issuance, not a path to self-funding. If the stock corrects, the ATM program becomes economically punishing or unavailable, compressing runway further.

4. Zero binding contracts since 2023 UAMPS cancellation (HIGH severity): NuScale's only firm commercial order cancelled in 2023 after estimated plant costs rose from ~$5.3B to ~$9.3B for 462 MWe — a 75% cost overrun before groundbreaking. Nearly three years later, no binding commercial contracts exist. The TVA/ENTRA1 6 GW "collaborative agreement" is a planning framework; the Romania FID has already slipped its stated deadline.

5. Operating loss acceleration (HIGH severity): FY2025 operating loss -$689.6M vs. FY2024 -$138.7M — nearly 5x increase in one year. Revenue of $31.5M against a -$689.6M operating loss reflects deeply negative operating leverage that will persist for years.

6. Competitive moat erosion (MEDIUM-HIGH severity): Oklo received NRC design criteria approval May 2026; Kairos has 14 NRC topical reports approved and a signed Google/TVA PPA; X-energy filed an S-1 with $94.3M trailing revenue and DOE backing. Oklo's $11.6B market cap exceeds NuScale's $4.5B despite no full NRC design certification — the market is pricing competitor pipelines at a premium to NuScale's regulatory head-start.

7. UAMPS cost-escalation precedent (HIGH severity): The 2023 cancellation is empirical evidence that NuScale's 50 MWe modules could not be built at a cost that made the electricity economically competitive. The 77 MWe uprated design and VOYGR-12 configuration are the theoretical answer, but they are unbuilt. Until a plant is actually constructed and operated at cost, economic viability remains unproven — and the one real-world data point was sharply negative.

8. Retail promotion profile (MEDIUM severity): Near-daily coverage from StocksToTrade and TimothySykes (known retail momentum publishers) in May-June 2026; Motley Fool "mark your calendar" urgency headline (May 23, 2026); the stock ran ~40% in 6 weeks on no new binding commercial news. Analyst price targets span $7–$45 (6x range). The stock trades on narrative and is susceptible to sharp mean-reversion when catalysts disappoint. These signals match a promotion-adjacent profile but fall short of a confirmed coordinated paid-promotion campaign.

• The BEAR analysis contained an arithmetic error: FY2024 revenue of $37.0M was +62.4% above FY2023's $22.8M — not "-14.9% on FY2023" as stated. The -14.9% figure correctly describes the FY2025 decline from FY2024. The overall bear thesis is not affected, but the revenue trajectory is materially better than the error implied: FY2024 was a strong growth year before FY2025's dip.

• The Q1 2026 share count figure used by both BULL and BEAR ("~237M") is the 2022-05-03 XBRL figure — the actual current float is substantially larger after the February 2026 75.9M-share offering, ongoing ATM activity, and other issuances. Any dilution multiple calculated against ~237M is understated.

• Oklo at $11.6B market cap vs. NuScale at $4.5B despite no full NRC design certification is a striking market signal: investors are pricing Oklo's hyperscaler-anchored customer pipeline above NuScale's regulatory head-start. This is not irrational — a signed contract with Meta for 1.2 GW is arguably more commercially valuable than an NRC certification with no paying customer.

• The DOE loan guarantee application has been on file since 2017 — nine years — without a conditional commitment. The Energy Secretary's "almost certainly" comment to Congress in April 2026 is a policy aspiration, not an administrative action.

NuScale is a genuine first-mover on NRC regulatory approval and is positioned in a structural demand wave that is real. But regulatory moats only create value if converted into commercial revenue — and three years after its only firm contract cancelled, NuScale has not closed a single binding order. The financial trajectory is deteriorating: operating cash burn accelerated 4.2x in FY2025 and the Q1 2026 press-release figures suggest further acceleration. The company is on a dilution treadmill by design.

The honest framing: this is a high-variance binary position. If RoPower FID or TVA/ENTRA1 converts to a binding agreement in 2026, the stock re-rates sharply and the regulatory moat becomes commercially real for the first time. If neither converts — the base case given the pattern of slippage — the stock drifts toward Citi's $7 target as dilution compounds and competitors close the regulatory gap. The 40% run in six weeks on no new binding news (driven by DOE policy rhetoric and AI narrative) reflects the stock's susceptibility to both sharp rallies and sharp reversals on sentiment alone. At $13.95, the price is in the middle of a wide and honestly uncertain fair-value range.

Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.